Table 2.
Characteristics of hemodialysis patients and healthy controls after the propensity score matching based on age and gender.
| MHD patients (n = 24) | Healthy controls (n = 24) | p value | |
|---|---|---|---|
| Male, % | 8 (33.3) | 10 (41.7) | .551 |
| Age, yr | 56.3 ± 9.6 | 54.6 ± 6.1 | .467 |
| BMI, kg/m2 | 21.8 (21.2–26.0) | 23.6 (21.3–27.1) | .491 |
| Laboratory parameters | |||
| Hemoglobin, g/L | 115.8 ± 13.3 | 135 ± 17.2 | .001 |
| WBC, ×109/L | 6.4 ± 1.4 | 5.4 ± 1.4 | .014 |
| Neutrophil, ×109/L | 4.3 ± 1.4 | 3.1 ± 1.2 | .002 |
| Lymphocyte, ×109/L | 1.5 (1.1–2.0) | 2.1 (1.7–2.4) | .001 |
| Monocyte, ×109/L | 0.35 (0.28–0.44) | 0.37 (0.28–0.43) | .959 |
| PLT, ×109/L | 196.0 ± 54.8 | 208.8 ± 54.7 | .423 |
| TP, g/L | 67.0 (64.0–70.0) | 65.5 (63.0–68.5) | .167 |
| SCr, μmol/L | 1014.3 ± 227.8 | 71.0 ± 14.6 | .000 |
| BUN, mmol/L | 26.0 ± 4.7 | 5.3 ± 1.2 | .000 |
| SUA, μmol/L | 426 ± 66.1 | 322.9 ± 79.8 | .000 |
| Glucose, mmol/L | 6.75 (5.5–9.1) | 4.9 (4.6–5.2) | .000 |
| Ca, mmol/L | 2.35 (2.21–2.46) | 2.26 (2.21–2.33) | .149 |
| P, mmol/L | 2.3 ± 0.5 | 1.2 ± 0.2 | .000 |
| Mg, mmol/L | 1.14 (1.05–1.31) | 0.88 (0.82–0.90) | .000 |
| β2-MG, mg/L | 39.4 ± 9.5 | ||
| spKt/V | 1.3 (1.1–1.5) | ||
| NT-proBNP, pg/mL | 3339.0 (1466.3–6830.0) | ||
| Ferritin, ng/mL | 184.0 (91.7–427.4) | ||
| TRF, g/L | 1.8 (1.6–2.0) | ||
| hsCRP, mg/L | 4.3 (1.4–9.6) | ||
| Ultrasonic cardiogram | |||
| PASP, mmHg | 30.5 (28.0–35.8) | 29.0 (25.0–32.0) | .107 |
| LVEF, % | 65.5 (59.3–67.8) | 68.0 (64.0–70.0) | .050 |
BMI: body mass index; BUN: serum blood urine nitrogen; Ca: serum calcium; hsCRP: high sensitivity C-reactive protein; LVEF: left ventricular ejection fraction; Mg: serum magnesium; NT-proBNP: N-terminal pro-B-type natriuretic peptide; P: serum phosphorus; PASP: pulmonary artery systolic pressure; SCr: serum creatinine; SUA: serum uric acid; TP: total protein; TRF: transferrin; β2-MG: serum beta 2 microglobulin; WBC: white blood cells.